Scilight Press

Author Information

Received: 15 Nov 2024 | Accepted: 15 Nov 2024 | Published: 18 Nov 2024

References 

• 1.
  Huntsman, D.G.; Ladanyi, M. The molecular pathology of cancer: From pan-genomics to post-genomics. J. Pathol. 2018, 244, 509–511. https://doi.org/10.1002/path.5057.
• 2.
  Kuipers, J.; Thurnherr, T.; Moffa, G.; Suter, P.; Behr, J.; Goosen, R.; Christofori, G.; Beerenwinkel, N. Mutational interactions define novel cancer subgroups. Nat. Commun. 2018, 9, 4353. https://doi.org/10.1038/s41467-018-06867-x.
• 3.
  Kalkat, M.; De Melo, J.; Hickman, K.A.; Lourenco, C.; Redel, C.; Resetca, D.; Tamachi, A.; Tu, W.B.; Penn, L.Z. MYC deregulation in primary human cancers. Genes 2017, 8, 151. https://doi.org/10.3390/genes8060151.
• 4.
  Curigliano, G.; Burstein, H.J.; Winer, E.P.; Gnant, M.; Dubsky, P.; Loibl, S.; Colleoni, M.; Regan, M.M.; Piccart-Gebhart, M.; Senn, H.J.; et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 2017, 28, 1700–1712. https://doi.org/10.1093/annonc/mdx308.
• 5.
  Amatu, A.; Sartore-Bianchi, A.; Siena, S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016, 1, e000023. https://doi.org/10.1136/esmoopen-2015-000023.
• 6.
  Qin, B.D.; Jiao, X.D.; Liu, K.; Wu, Y.; He, X.; Liu, J.; Qin, W.X.; Wang, Z.; Zang, Y.S. Basket trials for intractable Cancer. Front. Oncol. 2019, 9, 229. https://doi.org/10.3389/fonc.2019.00229.
• 7.
  Offin, M.; Liu, D.; Drilon, A. Tumor-agnostic drug development. Am. Soc. Clin. Oncol. Educ. Book 2018, 38, 184–187. https://doi.org/10.1200/edbk_200831.